MedPath

The evaluation of symptom and pathophysiological changes after 20mg of esomeprazole administration by 24-hour intraesophageal pH/impedance (MII-pH) monitoring.

Not Applicable
Conditions
PPI-resistant gastro-esophageal reflux disease
Registration Number
JPRN-UMIN000009264
Lead Sponsor
Division of Gastroenterology, Aichi Medical University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

(1)alarm sign such as vomitting or gastrointestinal bleeding (2)Zollinger Ellison syndrome, esophageal stenosis, achalasia, cerebrovascular disorder (3)Serious hepatic disorder, renal disease, heart disorder (4)malignant disorder (5)A pregnant woman, nursing mother or the woman who may be pregnant. (6)In addition, clinical studies supervisor or the study attending physician judged the subject to be inadequate to attend this study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
symptom, QOL, neurosis evaluation by questionnaire
Secondary Outcome Measures
NameTimeMethod
pathophysiology of GERD by 24-hour intraesophageal pH/impedance monitoring, HP infection, gastric mucosal atropy, CYP2C19 genetic polymorphism
© Copyright 2025. All Rights Reserved by MedPath